EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ba Cas12a3 represents a new subtype of type V CRISPR effector with collateral activity toward tRNA

Xin Li, Chenwei Wu, Jinshan Guo, Ruyi Zheng, Jingwen Kong, Lei Du, Qunxin She iD, Shiqi Ji iD

Nucleic Acids Research · 2026

DOI: 10.1093/nar/gkag915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Xin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: CRISPR and Archaea Biology Research Center, Microbial Technology Institute and State Key Laboratory of Microbial Technology, Shandong University, 72 …. Hauptthemen laut MEDLINE: RNA, Transfer, CRISPR-Cas Systems, CRISPR-Associated Proteins, Bacterial Proteins. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural Joint Program Fund, NIGMS NIH HHS, State Key Laboratory of Microbial Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR–Cas12 family encompasses diverse RNA-guided nucleases with both DNA- and RNA-targeting subtypes. They can trigger antiviral activities through either direct elimination of invading nucleic acids or activating broad collateral cleavage to induce abortive infection. Here, we report a novel type V CRISPR effector BaCas12a3 that causes growth inhibition through a unique tRNA-cleavage mechanism. Plasmid interference and western blot assays showed that BaCas12a3 induces host growth arrest without DNA damage response, suggestive of the absence of double-strand DNA breaks. Indeed, biochemical characterization of the BaCas12a3–crRNA ribonucleoprotein unraveled that the effector is an RNA-activating nuclease that cleaves the 3′ terminal CCA of tRNAs. Cryo-EM structures of BaCas12a3 reveal a conserved bilobed architecture featuring a unique tRNA-loading domain (tRLD) adjacent to the RuvC catalytic center. Structural and mutagenesis analyses show that the tRLD domain, together with a zinc ribbon domain, form a gated substrate groove. Target RNA binding induces conformational changes that open the groove and expose the RuvC active site, enabling specific tRNA 3′ end cleavage while preventing other non-specific degradation. Our findings identify the tRLD domain aside the RuvC active site responsible for the tRNA recognition in BaCas12a3, expanding the functional diversity of CRISPR immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, TransferCRISPR-Cas SystemsCRISPR-Associated ProteinsBacterial ProteinsModels, MolecularCryoelectron MicroscopyCatalytic Domain

Substanzen

RNA, TransferCRISPR-Associated ProteinsBacterial Proteins

Autor:innen und Institutionen

  • CRISPR and Archaea Biology Research Center, Microbial Technology Institute and State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Jimo, Qingdao, Shandong 266237, P.R. China.
  • National Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan 430070, P.R. China.

ORCID-Profile: Qunxin She, Shiqi Ji

Förderung

  • Intramural Joint Program Fund
  • NIGMS NIH HHS
  • State Key Laboratory of Microbial Technology
  • Shandong University
  • Frontiers and Challenges Projects
  • National Key Research and Development Program of China

Zitieren

APA

Li, X., Wu, C., Guo, J., Zheng, R., Kong, J., Du, L., She, Q., & Ji, S. (2026). Ba Cas12a3 represents a new subtype of type V CRISPR effector with collateral activity toward tRNA. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag915

Vancouver

Li X, Wu C, Guo J, Zheng R, Kong J, Du L, et al. Ba Cas12a3 represents a new subtype of type V CRISPR effector with collateral activity toward tRNA. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag915

BibTeX
@article{Li2026,
  author = {Li, Xin and Wu, Chenwei and Guo, Jinshan and Zheng, Ruyi and Kong, Jingwen and Du, Lei and She, Qunxin and Ji, Shiqi},
  title = {Ba Cas12a3 represents a new subtype of type V CRISPR effector with collateral activity toward tRNA},
  journal = {Nucleic Acids Research},
  year = {2026},
  doi = {10.1093/nar/gkag915}
}
Kostenlos starten →